229 related articles for article (PubMed ID: 16563806)
1. Optimisation and validation of a medium-throughput electrophysiology-based hERG assay using IonWorks HT.
Bridgland-Taylor MH; Hargreaves AC; Easter A; Orme A; Henthorn DC; Ding M; Davis AM; Small BG; Heapy CG; Abi-Gerges N; Persson F; Jacobson I; Sullivan M; Albertson N; Hammond TG; Sullivan E; Valentin JP; Pollard CE
J Pharmacol Toxicol Methods; 2006; 54(2):189-99. PubMed ID: 16563806
[TBL] [Abstract][Full Text] [Related]
2. Characterization of a hERG screen using the IonWorks HT: comparison to a hERG rubidium efflux screen.
Sorota S; Zhang XS; Margulis M; Tucker K; Priestley T
Assay Drug Dev Technol; 2005 Feb; 3(1):47-57. PubMed ID: 15798395
[TBL] [Abstract][Full Text] [Related]
3. Optimisation and validation of a medium-throughput electrophysiology-based hNav1.5 assay using IonWorks.
Harmer AR; Abi-Gerges N; Easter A; Woods A; Lawrence CL; Small BG; Valentin JP; Pollard CE
J Pharmacol Toxicol Methods; 2008; 57(1):30-41. PubMed ID: 17980627
[TBL] [Abstract][Full Text] [Related]
4. Development of a high-throughput electrophysiological assay for the human ether-à-go-go related potassium channel hERG.
Gillie DJ; Novick SJ; Donovan BT; Payne LA; Townsend C
J Pharmacol Toxicol Methods; 2013; 67(1):33-44. PubMed ID: 23103595
[TBL] [Abstract][Full Text] [Related]
5. Validation of a medium-throughput electrophysiological assay for KCNQ2/3 channel enhancers using IonWorks HT.
Jow F; Shen R; Chanda P; Tseng E; Zhang H; Kennedy J; Dunlop J; Bowlby MR
J Biomol Screen; 2007 Dec; 12(8):1059-67. PubMed ID: 18087070
[TBL] [Abstract][Full Text] [Related]
6. Rb+ flux through hERG channels affects the potency of channel blocking drugs: correlation with data obtained using a high-throughput Rb+ efflux assay.
Rezazadeh S; Hesketh JC; Fedida D
J Biomol Screen; 2004 Oct; 9(7):588-97. PubMed ID: 15475478
[TBL] [Abstract][Full Text] [Related]
7. Electrophysiological analysis of mammalian cells expressing hERG using automated 384-well-patch-clamp.
Haraguchi Y; Ohtsuki A; Oka T; Shimizu T
BMC Pharmacol Toxicol; 2015 Dec; 16():39. PubMed ID: 26671227
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the rubidium efflux assay for preclinical identification of HERG blockade.
Chaudhary KW; O'Neal JM; Mo ZL; Fermini B; Gallavan RH; Bahinski A
Assay Drug Dev Technol; 2006 Feb; 4(1):73-82. PubMed ID: 16506891
[TBL] [Abstract][Full Text] [Related]
9. Comparison of human Ether-à-go-go related gene screening assays based on IonWorks Quattro and thallium flux.
Bridal TR; Margulis M; Wang X; Donio M; Sorota S
Assay Drug Dev Technol; 2010 Dec; 8(6):755-65. PubMed ID: 20658944
[TBL] [Abstract][Full Text] [Related]
10. Improved throughput of PatchXpress hERG assay using intracellular potassium fluoride.
Zeng H; Penniman JR; Kinose F; Kim D; Trepakova ES; Malik MG; Dech SJ; Balasubramanian B; Salata JJ
Assay Drug Dev Technol; 2008 Apr; 6(2):235-41. PubMed ID: 18471077
[TBL] [Abstract][Full Text] [Related]
11. A pharmacologically validated, high-capacity, functional thallium flux assay for the human Ether-à-go-go related gene potassium channel.
Schmalhofer WA; Swensen AM; Thomas BS; Felix JP; Haedo RJ; Solly K; Kiss L; Kaczorowski GJ; Garcia ML
Assay Drug Dev Technol; 2010 Dec; 8(6):714-26. PubMed ID: 21158686
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of functional and binding assays in cells expressing either recombinant or endogenous hERG channel.
Murphy SM; Palmer M; Poole MF; Padegimas L; Hunady K; Danzig J; Gill S; Gill R; Ting A; Sherf B; Brunden K; Stricker-Krongrad A
J Pharmacol Toxicol Methods; 2006; 54(1):42-55. PubMed ID: 16326118
[TBL] [Abstract][Full Text] [Related]
13. A place for high-throughput electrophysiology in cardiac safety: screening hERG cell lines and novel compounds with the ion works HTTM system.
Guthrie H; Livingston FS; Gubler U; Garippa R
J Biomol Screen; 2005 Dec; 10(8):832-40. PubMed ID: 16234341
[TBL] [Abstract][Full Text] [Related]
14. A quantitative assessment of hERG liability as a function of lipophilicity.
Waring MJ; Johnstone C
Bioorg Med Chem Lett; 2007 Mar; 17(6):1759-64. PubMed ID: 17239590
[TBL] [Abstract][Full Text] [Related]
15. Automated electrophysiology in the preclinical evaluation of drugs for potential QT prolongation.
Guo L; Guthrie H
J Pharmacol Toxicol Methods; 2005; 52(1):123-35. PubMed ID: 15936217
[TBL] [Abstract][Full Text] [Related]
16. The [3H]dofetilide binding assay is a predictive screening tool for hERG blockade and proarrhythmia: Comparison of intact cell and membrane preparations and effects of altering [K+]o.
Diaz GJ; Daniell K; Leitza ST; Martin RL; Su Z; McDermott JS; Cox BF; Gintant GA
J Pharmacol Toxicol Methods; 2004; 50(3):187-99. PubMed ID: 15519905
[TBL] [Abstract][Full Text] [Related]
17. hERG potency estimates based upon dose solution analysis: What have we learned?
Qu Y; Schnier P; Zanon R; Vargas HM
J Pharmacol Toxicol Methods; 2011; 64(3):251-7. PubMed ID: 21888984
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of cardiac HERG currents by the DNA topoisomerase II inhibitor amsacrine: mode of action.
Thomas D; Hammerling BC; Wu K; Wimmer AB; Ficker EK; Kirsch GE; Kochan MC; Wible BA; Scholz EP; Zitron E; Kathöfer S; Kreye VA; Katus HA; Schoels W; Karle CA; Kiehn J
Br J Pharmacol; 2004 Jun; 142(3):485-94. PubMed ID: 15148258
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of a high-throughput fluorescence assay method for HERG potassium channel inhibition.
Dorn A; Hermann F; Ebneth A; Bothmann H; Trube G; Christensen K; Apfel C
J Biomol Screen; 2005 Jun; 10(4):339-47. PubMed ID: 15964935
[TBL] [Abstract][Full Text] [Related]
20. Early evaluation of compound QT prolongation effects: a predictive 384-well fluorescence polarization binding assay for measuring hERG blockade.
Deacon M; Singleton D; Szalkai N; Pasieczny R; Peacock C; Price D; Boyd J; Boyd H; Steidl-Nichols JV; Williams C
J Pharmacol Toxicol Methods; 2007; 55(3):238-47. PubMed ID: 17141530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
